Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
作者信息
Connolly Caoilfhionn M, Teles Mayan, Frey Sarah, Boyarsky Brian J, Alejo Jennifer L, Werbel William A, Albayda Jemima, Christopher-Stine Lisa, Garonzik-Wang Jacqueline, Segev Dorry L, Paik Julie J
机构信息
Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
Ann Rheum Dis. 2022 Feb;81(2):291-293. doi: 10.1136/annrheumdis-2021-221206. Epub 2021 Sep 7.
Abstract
摘要
相似文献
1
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.自身免疫性疾病患者的新冠病毒加强剂量疫苗接种：病例系列
Ann Rheum Dis. 2022 Feb;81(2):291-293. doi: 10.1136/annrheumdis-2021-221206. Epub 2021 Sep 7.
2
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
3
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.霉酚酸临时停药增强风湿性和肌肉骨骼疾病患者对SARS-CoV-2疫苗的体液免疫反应：病例系列
Ann Rheum Dis. 2022 Feb;81(2):293-295. doi: 10.1136/annrheumdis-2021-221252. Epub 2021 Sep 23.
4
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.评估 BNT162b2 SARS-CoV-2 疫苗在医护人员、老年人和自身免疫性疾病免疫抑制患者中诱导的体液和细胞免疫。
Immunol Res. 2021 Dec;69(6):576-583. doi: 10.1007/s12026-021-09226-z. Epub 2021 Aug 21.
5
Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases.自身免疫性风湿病患者对SARS-CoV-2疫苗的体液免疫反应
Arch Med Res. 2025 Apr;56(3):103141. doi: 10.1016/j.arcmed.2024.103141. Epub 2025 Jan 6.
6
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响：初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
7
Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion.体液和细胞免疫对 B 细胞耗竭的自身免疫性疾病患者感染 SARS-CoV-2 及疫苗接种的反应。
Arthritis Rheumatol. 2022 Jan;74(1):33-37. doi: 10.1002/art.41914. Epub 2021 Nov 23.
8
Humoral immune response as an indicator for protection against Covid-19 after anti-SARS-COV2-booster vaccination in hematological and oncological patients.体液免疫反应作为抗 SARS-CoV-2 加强疫苗接种后预防血液系统和肿瘤患者 COVID-19 的指标。
Int J Cancer. 2024 Dec 15;155(12):2141-2148. doi: 10.1002/ijc.35162. Epub 2024 Sep 2.
9
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.与健康对照相比，免疫缺陷患者接种5剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后T细胞免疫增强，体液反应降低。
Front Immunol. 2025 Mar 6;16:1538453. doi: 10.3389/fimmu.2025.1538453. eCollection 2025.
10
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.接受免疫抑制治疗的患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞反应。
Ann Rheum Dis. 2021 Oct;80(10):1322-1329. doi: 10.1136/annrheumdis-2021-220626. Epub 2021 Aug 6.
引用本文的文献
1
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.硫嘌呤治疗的炎症性肠病患者对SARS-CoV-2疫苗的长期定量细胞反应受损。
Cells. 2025 Jul 26;14(15):1156. doi: 10.3390/cells14151156.
2
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.新冠疫情及疫苗接种运动对大流行头三年中1755例系统性硬化症患者的影响。在下一疫情阶段，免疫反应受损者、正在接受免疫调节治疗者以及患有疾病相关肺部病变者面临的潜在风险。
J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec.
3
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.由于抗病毒免疫反应受损，接受霉酚酸酯治疗的炎症性自身免疫性疾病或肝移植的疫苗接种患者 SARS-CoV-2 感染风险更高：前瞻性 RIVALSA 队列扩展随访的结果。
Front Immunol. 2023 Jul 20;14:1185278. doi: 10.3389/fimmu.2023.1185278. eCollection 2023.
4
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.COVID-19 时期血管炎患者的免疫抑制管理。
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
5
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.第三和第四剂疫苗可增强和延长免疫介导的炎症性疾病成年患者对 SARS-CoV-2 的免疫力。
J Immunol. 2023 Aug 1;211(3):351-364. doi: 10.4049/jimmunol.2300190.
6
Vaccine hesitancy in patients with COVID-19 who have back pain.患有背痛的新冠患者中的疫苗犹豫现象。
Osong Public Health Res Perspect. 2023 Apr;14(2):100-109. doi: 10.24171/j.phrp.2023.0003. Epub 2023 Mar 24.
7
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.BNT162b2 mRNA新冠疫苗第二剂和第三剂接种后在青少年起病的自身免疫性炎性风湿病患者中的安全性和免疫原性：一项前瞻性多中心研究
Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819.
8
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.接种过两剂和三剂疫苗的炎症性风湿病患者中 SARS-CoV-2 突破性感染的特征和结局。
RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2023-002998.
9
The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What.第四剂新冠疫苗的四个W：为何、何人、何时及何种。
Vaccines (Basel). 2022 Nov 14;10(11):1924. doi: 10.3390/vaccines10111924.
10
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients.COVID-19 加强针接种在炎症性关节炎患者中的体液和细胞免疫原性。
Front Immunol. 2022 Oct 31;13:1033804. doi: 10.3389/fimmu.2022.1033804. eCollection 2022.
本文引用的文献
1
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.BNT162b2 疫苗突破性感染：以色列 152 名完全接种疫苗的住院 COVID-19 患者的临床特征。
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657. doi: 10.1016/j.cmi.2021.06.036. Epub 2021 Jul 7.
2
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
3
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
4
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的高抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
5
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.风湿性和肌肉骨骼疾病患者接种两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗后无体液免疫反应：病例系列
Ann Intern Med. 2021 Sep;174(9):1332-1334. doi: 10.7326/M21-1451. Epub 2021 May 25.
Zotero 插件